SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001683168-24-008125
Filing Date
2024-11-14
Accepted
2024-11-14 17:00:18
Documents
44
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q FOR SEPT 2024 cns_i10q-093024.htm   iXBRL 10-Q 556174
2 CERTIFICATION BY CHIEF EXECUTIVE OFFICER cns_ex3101.htm EX-31.1 6839
3 CERTIFICATION BY CHIEF FINANCIAL OFFICER cns_ex3102.htm EX-31.2 6885
4 CERTIFICATION OF CHIEF EXECUTIVE OFFICER cns_ex3201.htm EX-32.1 3050
5 CERTIFICATION OF CHIEF FINANCIAL OFFICER cns_ex3202.htm EX-32.2 3118
  Complete submission text file 0001683168-24-008125.txt   3382465

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE cnsp-20240930.xsd EX-101.SCH 24557
7 XBRL CALCULATION FILE cnsp-20240930_cal.xml EX-101.CAL 27294
8 XBRL DEFINITION FILE cnsp-20240930_def.xml EX-101.DEF 125919
9 XBRL LABEL FILE cnsp-20240930_lab.xml EX-101.LAB 278928
10 XBRL PRESENTATION FILE cnsp-20240930_pre.xml EX-101.PRE 226051
46 EXTRACTED XBRL INSTANCE DOCUMENT cns_i10q-093024_htm.xml XML 353332
Mailing Address 2100 WEST LOOP SOUTH SUITE 900 HOUSTON TX 77027
Business Address 2100 WEST LOOP SOUTH SUITE 900 HOUSTON TX 77027 1-800-946-9185
CNS Pharmaceuticals, Inc. (Filer) CIK: 0001729427 (see all company filings)

IRS No.: 822318545 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39126 | Film No.: 241463948
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)